Atea Pharmaceuticals

General Information
Business:

 

We are a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Leveraging our deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, we have built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, we are focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, the virus that causes COVID-19, hepatitis C virus, or HCV, dengue virus, and respiratory syncytial virus, or RSV. We believe our team’s expertise from decades of developing innovative antiviral treatments uniquely positions us to advance medicines that have the potential to cure some of the world’s most severe viral diseases by inhibiting the enzymes central to viral replication.

Industry: Pharmaceuticals
Employees: 19
Founded: 2012
Contact Information
Address 125 Summer Street Boston, MA 02110
Phone Number (857) 284-8891
Web Address http://www.ateapharma.com/
View Prospectus: Atea Pharmaceuticals
Financial Information
Market Cap $1937.8mil
Revenues $0 mil (last 12 months)
Net Income $-22.3 mil (last 12 months)
IPO Profile
Symbol AVIR
Exchange NASDAQ
Shares (millions): 12.5
Price range $24.00 - $24.00
Est. $ Volume $300.0 mil
Manager / Joint Managers J.P. Morgan/ Morgan Stanley/ Evercore ISI/ William Blair
CO-Managers -
Expected To Trade: 10/30/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change